|
|
Deficient neurotransmitter systems and synaptic function in frontotemporal lobar degeneration : insights into disease mechanisms and current therapeutic approaches |
|---|---|
| Author: | Huber, Nadine1; Korhonen, Sonja1; Hoffmann, Dorit1; |
| Organizations: |
1A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland 2Unit of Clinical Neuroscience, Neurology, University of Oulu, P. O. Box 8000, University of Oulu, FI-90014, Oulu, Finland 3MRC Oulu, Oulu University Hospital, P. O. Box 8000, University of Oulu, FI-90014, Oulu, Finland
4School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70210, Kuopio, Finland
5Department of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA 6Institute of Clinical Medicine—Neurology, University of Eastern Finland, P.O. Box 1627, FI-70210, Kuopio, Finland 7Neuro Center, Neurology, Kuopio University Hospital, P.O. Box 100, KYS, FI-70029, Kuopio, Finland |
| Format: | article |
| Version: | published version |
| Access: | open |
| Online Access: | PDF Full Text (PDF, 1.1 MB) |
| Persistent link: | http://urn.fi/urn:nbn:fi-fe2022112366565 |
| Language: | English |
| Published: |
Springer Nature,
2022
|
| Publish Date: | 2022-11-23 |
| Description: |
AbstractFrontotemporal lobar degeneration (FTLD) comprises a heterogenous group of fatal neurodegenerative diseases and, to date, no validated diagnostic or prognostic biomarkers or effective disease-modifying therapies exist for the different clinical or genetic subtypes of FTLD. Current treatment strategies rely on the off-label use of medications for symptomatic treatment. Changes in several neurotransmitter systems including the glutamatergic, GABAergic, dopaminergic, and serotonergic systems have been reported in FTLD spectrum disease patients. Many FTLD-related clinical and neuropsychiatric symptoms such as aggressive and compulsive behaviour, agitation, as well as altered eating habits and hyperorality can be explained by disturbances in these neurotransmitter systems, suggesting that their targeting might possibly offer new therapeutic options for treating patients with FTLD. This review summarizes the present knowledge on neurotransmitter system deficits and synaptic dysfunction in model systems and patients harbouring the most common genetic causes of FTLD, the hexanucleotide repeat expansion in C9orf72 and mutations in the granulin (GRN) and microtubule-associated protein tau (MAPT) genes. We also describe the current pharmacological treatment options for FLTD that target different neurotransmitter systems. see all
|
| Series: |
Molecular psychiatry |
| ISSN: | 1359-4184 |
| ISSN-E: | 1476-5578 |
| ISSN-L: | 1359-4184 |
| Volume: | 27 |
| Issue: | 3 |
| Pages: | 1300 - 1309 |
| DOI: | 10.1038/s41380-021-01384-8 |
| OADOI: | https://oadoi.org/10.1038/s41380-021-01384-8 |
| Type of Publication: |
A2 Review article in a scientific journal |
| Field of Science: |
3124 Neurology and psychiatry |
| Subjects: | |
| Copyright information: |
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
|
https://creativecommons.org/licenses/by/4.0/ |